{"filing":{"accession_number":"0001213900-26-090478","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"ea0302324-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026090478/ea0302324-6k_canfite.htm"},"events":[{"id":28076,"run_id":25660,"accession_number":"0001213900-26-090478","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine in pancreatic cancer, providing mechanistic support for Can-Fite's planned Phase IIb study. While the disclosure concerns drug development progress and clinical trial advancement—core operational matters for a clinical-stage biotech—it does not fit the specific event types of earnings_release (no financial results), material_litigation, or other named categories. The announcement of positive preclinical data supporting an upcoming Phase IIb trial represents a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's pipeline progress and development strategy.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":[{"id":29876,"accession_number":"0001213900-26-090478","item_number":"EX-99.1","item_title":"ea030232401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine in pancreatic cancer, providing mechanistic support for Can-Fite's planned Phase IIb study. While the disclosure concerns drug development progress and clinical trial advancement—core operational matters for a clinical-stage biotech—it does not fit the specific event types of earnings_release (no financial results), material_litigation, or other named categories. The announcement of positive preclinical data supporting an upcoming Phase IIb trial represents a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's pipeline progress and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:56:15.651191+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29876,"accession_number":"0001213900-26-090478","item_number":"EX-99.1","item_title":"ea030232401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine in pancreatic cancer, providing mechanistic support for Can-Fite's planned Phase IIb study. While the disclosure concerns drug development progress and clinical trial advancement—core operational matters for a clinical-stage biotech—it does not fit the specific event types of earnings_release (no financial results), material_litigation, or other named categories. The announcement of positive preclinical data supporting an upcoming Phase IIb trial represents a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's pipeline progress and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:56:15.651191+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-17"}]}